Jessica Fai

“For the off-treatment data set coming up in the first quarter of 27, how many patients will there be, and could you remind us of your expectations for RESPEX, effect size, and biologic experience patients compared to 90 patients in AD?”

“I was looking at the press release, and it looks like there's a lot of regulatory submissions going in in the first half of 2027. And I was curious if you could just speak to kind of the organizational bandwidth to bring in additional assets via business development during what seems like a really busy time.”

“Can we expect you to guide for Brin Supri in January, similar to what you've historically done for Era Case? And then on TPIP, congrats on the enrollment traction in the ILD trial.”

“On today's call, you will hear from Howard Robin, our President and Chief Executive Officer, Dr. Jonathan Zaleski, our Chief Research and Development Officer, and Linda Rubenstein, our Chief Financial Officer.”

“I had two kind of on the financial side. First, can you just expand a little bit on the comments you made about how to think about the revenue cadence in 3Q and 4Q?”